In a retrospective analysis of 32 Taiwanese patients with ALK-positive NSCLC treated with crizotinib and followed up for a median of 493 days, significant cystic changes in the kidneys were observed in 7 patients (22%), most of which regressed after discontinuation of crizotinib.22 This evidence concerns the gene ALK and non-small cell lung carcinoma.